On
During the reporting period, the Company's operating revenue increased by 87.8% YOY to
In 2022, the gross profit margin climbed to 75.6%. Gross profit for the year rose to
Zylox-Tonbridge also delivered an outstanding performance in terms of R&D and commercialization. As of the date of the results announcement, the Company owned a portfolio of 57 products and product candidates, of which 25 had received marketing approval from the
'2022 was a challenging year. With efficient product development, strong team execution, and improving operational capabilities, the Company has achieved substantial growth in financial performance by leveraging market opportunities,' said Dr.
STRONG R&D CAPABILITIES LEAD TO THE EXPANSION OF NEW THERAPEUTIC AREAS
With the launch and commercialization of several new products in 2022, Zylox-Tonbridge once again made great progress in R&D, driving its expansion into new therapeutic areas and positioning the firm to become a leading vascular interventional medical devices platform in
Zylox-Tonbridge's self-developed Carotid Rx PTA Balloon Catheter is the first in its Carotid Artery Stenosis product line to receive marketing approval from NMPA. Relying on the firm's leading balloon forming and manufacturing platform for its development, the solution received significant attention in the marketplace as soon as it was launched. Marketing approval for the Endovenous Radiofrequency Ablation (RFA) System as well as the ZYLOX Octoplus Vena Cava Filter is a testament to the success of the Company's expansion into the domain of peripheral venous vascular diseases treatment.
The results announcement shows that Zylox-Tonbridge completed patient enrollment for clinical trials of 5 products in 2022, including the Flow Diverter and Peripheral Detachable Embolization Coils. Currently, the Company has 13 products in the clinical stage and 11 in the registration stage. With the coming launch of several core products in the future one or two years, including Flow Diverter, Peripheral Venous Stent System, and Vascular Closure, the Company is accelerating sustainable growth driven by its strong R&D capability.
INCREASING PENETRATION IN THE DOMESTIC MARKET WHILE ACCELERATING GLOBAL EXPANSION
Last year, with a flexible, effective market strategy alongside the team's efficient execution, Zylox-Tonbridge further grew its sales network in tandem with an expansion of its market penetration.
To date, Zylox-Tonbridge has established an extensive distribution network covering over 3,300 hospitals in 31 provinces and municipalities across
With a deep commitment to
FOCUS ON LONG-TERM GROWTH STRATEGY WITH IMPROVING EFFICIENCY
In 2022, Zylox-Tonbridge further enhanced its efficiency in R&D, manufacturing, and commercialization with an ongoing commitment to achieving long-term, quality-driven growth.
Relying on multiple innovative technology platforms across business units as well as integrated R&D and manufacturing processes, Zylox-Tonbridge has improved cost efficiency and product quality while maintaining its strong R&D capability. To better respond to increasing market demand, the Company is expanding larger-scale manufacturing facilities in
Following the launch and commercialization of several new medical devices in 2022, Zylox-Tonbridge is enhancing its competence in offering a comprehensive range of medical device solutions and is well on track to becoming a leading vascular interventional medical device platform. The firm plans to continue expanding its innovative product portfolio as well as improving R&D and manufacturing capabilities as part of its efforts to benefit patients by providing them with quality and affordable solutions.
Contact:
Tel: +86-57188610082
Email: info@zyloxtb.com
(C) 2023 Electronic News Publishing, source